Comprehensive Textbook of Genitourinary Oncology.
Publication Date: 2011
Availability: In Stock
ISBN/ISSN: 9781608313525


Comprehensive Textbook of Genitourinary Oncology was the first major textbook to focus on the field of genitourinary oncology from the combined perspectives of the molecular biologist, pathologist, oncologist and urologist. The first edition of the book had three fundamental goals: 1) to be a textbook that could be read and used by practicing physicians, 2) to be an authoritative textbook for basic scientists, 3) to be an effective interpretation of this field for trainees in surgery, medical and radiation oncology, and pathology. The goals for the 4th edition remain essentially the same. The book takes a systems approach to this field, with sections on prostate, bladder, kidney, testis, and penile cancers, as well as one each on pediatric and other (less common) malignancies. This volume will introduce and distill the combined knowledge and expertise of specialist from a multitude of scientific and clinical disciplines who are internationally recognized leaders in their fields and who themselves have contributed to the field. As in the last edition, authors will be drawn form the fields of urological surgery, medical oncology, radiation oncology, pathology, radiology as well as translational scientists and epidemiologists.
Rights Link

Go to Cart
--NEW! Covers merging image-guided targeted technologies such as magnetic resonance image-guided high-intensity focused ultrasound, which can precisely ablate cancerous cells without damage to surrounding healthy tissue.
--NEW! Greater focus on the multidisciplinary care of patients with urological cancers with improved outcomes dependent on collaborative development of care plans that incorporate evidence-based management.
--NEW! Includes new imaging modalities including diffusion-weighted imaging and magnetic resonance spectroscopic imaging which help clinicians differentiate tumor subtypes and target treatment
--NEW! Increase coverage of molecular classification of cancers and the delineation of critical pathways that can identify new targets for systemic therapy and demonstrate how cells react to particular drugs.
--NEW! Reviews combined imaging technology, such as MR-ultrasound fusion to better guide needle biopsies, and PET-CT imaging to identify and locate biologically active metastatic lesions, as well as novel radiotracers highly specific for key molecules present in
--NEW! Summarize and evaluate the latest research on existing and investigational new drugs.
--Most comprehensive GU cancer book on the market
--Editors represent each of the major sub areas in this field (Vogelzang/medical oncology, Scardino/urology (prostate), Zelefsky/radiation oncology, and Linehan/urology (kidney)
--Multi-modality approach of the book reflects the way in which these cancers are managed and encourages multidisciplinary sales opportunities
W. Marston Linehan MD
Chief, Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Peter T. Scardino MD
Florence and Theodore Baumritter/Enid Ancell Chair, Chairman, Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY

Nicholas J. Vogelzang MD
Director, Nevada Cancer Institute, Las Vegas, NV

Edition: 4
ISBN/ISSN: 9781608313525
Product Format: Hardbound
Trim Size: 8.375 x 10.875
Pages: 973
Pub Date: 2011
Weight: 6.1
1:   Epidemiology of Prostate Cancer
Edward Giovannucci, Elizabeth A. Platz, and Lorelei Mucci
2:   Genetic Basis of Prostate Cancer
Stacy Loeb and William B. Isaacs
3:   Androgen Receptor Signaling in Castrate Resistant Prostate Cancer
Brett S. Carver and Charles L. Sawyers
4:    Anatomy and Pathology of Prostate Cancer
4A: Anatomy of the Prostate and the Pathology of Prostate Cancer
Peter A. Humphrey
4B: Prostate Cancer: Molecular Pathology and Biologic Determinants
Massimo F. Loda
4C: Ets Genes and Prostate Cancer: Implications for Prognosis and Disease Control
Jeremy P. Clark and Colin S. Cooper
5:    Prevention of Prostate Cancer         
Barbara Ercole, Javier Hernandez, and Ian M. Thompson, Jr.
6 :   Screening and Early Detection
6A: Early Detection of Prostate Cancer with PS
Stacy Loeb and William J. Catalona
6B: Screening for Prostate Cancer
Freddie C. Hamdy, Jenny L. Donovan, and David E. Neal
7:   Prostate Needle Biopsy Techniques and Interpretation
Katsuto Shinohara, Viraj A, Thomas Chi, and Peter R. Carroll
8:   Staging Systems for Prostate Cancer
Alison M. Lake and Sam S. Chang
9:   Nomograms for Prostate Cancer Decision-Making
Andrew J. Stephenson and Michael W. Kattan
10:  Imaging in Prostate Cancer
Hedvig Hricak
11:   Treatment of Early Stage Prostate Cancer
11A: Quality of Life after Treatment for Early Stage Prostate Cancer
Mehrdad Alemozaffar and Martin G. Sanda
11B: Active Surveillance for Prostate Cancer: Rationale, Methods, and Results
Laurence Klotz
11C: PLND: Indications for and Technique of Pelvic Lymph Node Dissection
Fiona C. Burkhard and Urs E. Studer
11D: Radical Prostatectomy for Clinical Stage T1 and T2 Prostate Cancer
James A. Eastham and Peter T. Scardino
11E: Treatment of Early Stage Prostate Cancer: Laparoscopic Radical Prostatectomy
Karim Touijer and Bertrand Guillonneau
11F: Robotic-Assisted Laparoscopic Prostectomy
Joseph A. Smith, Jr.
11G: Brachytherapy Alone and with External Beam Radiotherapy for Localized Prostate Cancer     
Michael Zelefsky
11H: Other Interventions for the Treatment of Localized Prostate Cancer (Cryo, Hifu)
Stephen Jones and Ryan Berglund
12:    Management of High Risk Prostate Cancer
12A: Combined Hormone Therapy and Radiation Therapy for High-Risk Prostate Cancer
Michel Bolla and M. Roach
12B: Surgical Management of Clinical T3 (cT3) and Node Positive (pN+) Adenocarcinoma
Michael Blute and Jeffrey Karnes
13:   Treatment of Locally Recurrent Prostate Cancer
13A: Recurrence Following Radiotherapy: Definitions, Prognosis, and Management
Eric M. Horwitz and Gerald E. Hanks
13B: Salvage Radical Prostatectomy for Recurrence Prostate Cancer after Radiation Therapy        
James A. Eastham
13C: Salvage Brachytherapy for Prostate Cancer
Ryan J. Burri and Richard G. Stock
13D: Recurrence Following Radical Prostatectomy: Definitions and Management
Lionel L. Bañez, Stephen J. Freedland, and Judd W. Moul
13E: Adjuvant and Salvage Radiotherapy, Post-Prostatectomy
Dayssy Alexandra Diaz and Alan Pollack
14:   Advanced Prostate Cancer
14A: Biology of Bone Metastases in Men with Prostate Cancer
Matthew Smith and Mary Anne Fallon
14B:  Initial Management of Metastatic Prostate Cancer
Ajjai S. Alva and Maha Hussain
14C: Second Line Treatment: Going Beyond Hormones
Howard Scher, Kristofer Prepelica, and Nicholas Mitsiades
14D: Management of Castration-Resistant Prostate Cancer
Sonia M. Seng, Mari Nakabayashi, and William K. Oh
15:  The Epidemiology of Bladder Cancer          
Jian-Min Yuan and Heather H. Nelson
16:  Cytology and Pathology of Carcinomas of the Urinary Tract
Victor Reuter, Hikmat Al-Ahmadie, and Oscar Lin
17:   Molecular Biology and Prognostic Markers in Bladder Cancer
Anirban P. Mitra, Dan Theodorescu, Seth P. Lerner, Richard J. Cote, and Ram H. Datar
18:   Screening, Early Detection, and Prevention of Bladder Cancer
Antonio J Otero, H. Barton Grossman, and Colin P.N. Dinney
19:   Bladder Cancer Staging
Theresa M. Koppie and Bernard H. Bochner
20:   Imaging of Transitional Cell Carcinoma
Mukesh G. Harisinghani and Efrén J. Flores
21:   Upper Tract Tumors
21A: Management of Upper Tract Tumors
Guilherme Godoy and Seth P. Lerner
21B: Minimally-Invasive Surgical Procedures (Robotic, Laparoscopic, Single-Site) for Treatment of
Upper Tract Tumors
David A. Duchene and Howard N. Winfield
22:    Non Muscle Invasive Bladder Cancer
22A: Low Risk Non-Invasive Bladder Cancer
J. Alfred Witjes
22B: High Risk Non-Muscle Invasive Bladder Cancer: Ta High Grade and Carcinoma In-Situ 
Andrew J. Lightfoot, Henry M. Rosevear, and Michael A. O’Donnell
22C: Lamina Propria Invasive Bladder Cancer (T1)
Guido Dalbagni
23:    Invasive Bladder Cancer
23A: Radical Cystectomy & Pelvic Lymph Node Dissection
Bochner, Quek, Skinner
23B: Role of Radical Cystectomy in Patients with Advanced Bladder Cancer
S. Machele Donat and Harry W. Herr
23C: Management of Complications and Long Term Follow-up
Cheryl Lee
24:    Bladder Preservation Strategies for Invasive Bladder Cancer
24A: Trimodality Therapy: Selective Bladder Preservation in the Treatment of Muscle-invasive Bladder
Mohamed E. Abazeed, Jason A. Efstathiou, Niall M. Heney, Andrzej Niemierko, Donald S.
Kaufman, and William U. Shipley
24B:  Radical Transurethral Resection of the Bladder and Partial Cystectomy for Invasive Bladder
Eduardo Solsona
25:   Urinary Diversions and Reconstructions
25A: Cutaneous Urinary Diversions
G. Joel DeCastro, Michael C. Large, and Gary D. Steinberg
25B: Orthotopic Bladder Substitution
Richard Hautmann:, Urs Studer, Robert Mills, and William Turner
26:   Neo Adjuvant and Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer
Cora N. Sternberg
27:   Chemotherapy for Metastatic Bladder, Alone or in Combination with Other Treatment
Matthew Milowsky and Dean F. Bajorin
28:   Testis Cancer: Clinical Signs and Symptoms
Timothy A. Masterson and Stephen D. W. Beck
29:    The Epidemiology and Genetics of Sporadic and Hereditary Testicular Cancer
David Vaughn, Kate Nathanson, and Peter Kanetsky
30:    Biology and Genetics of Adult Male Germ Cell Tumors
Darren R. Feldman, Jane Houldsworth, George J. Bosl, and R. S. K. Chaganti
31:   Anatomy and Pathology of Testis Cancer
Victor Reuter
32:   Staging of Testicular Cancer
32A: Staging and Imaging in Germ Cell Tumors
Brett S. Carver and Darren R. Feldman
32B: The Role of Serum Tumor Markers in the Diagnosis and Management of Testicular  Cancer    
LaMont J. Barlow and James M. McKiernan
32C: Risk Assignment in Advanced Testis Cancer
Dean F. Bajorin
33:   Management of Low Stage Germ Cell Tumors of the Testis
33A: Management of Low-Stage Testicular Seminoma
Nathan Lawrentschuk and Neil E Fleshner
33B: Management of Low Stage Nonseminomatous Tumors
Andrew Stephenson and Tim Gilligan
33C: Radical Orchiectomy and Retroperitoneal Lymph Node Dissection
William T. Lowrance and Joel Sheinfeld
33D: Laparoscopic Retroperitoneal Lymph Node Dissection
Greg Trottier, Antonio Finelli, and Octavio Castillo
34:   Management of Advanced Germ Cell Tumors
34A: Risk-Adapted Therapy of Metastatic Testis Cancer: Good-Risk Patients 
Stefan Sleijfer and Ronald de Wit
34B: Management of Advanced Germ Cell Tumors: IGCCC Intermediate and Poor Risk Patients     
Peter Grimison and Guy C. Toner
34C: Management of Relapsed Patients
Darren Feldman, George J. Bosl, and Robert Motzer
34D: Role of Post-Chemotherapy Surgery in Germ Cell Tumors
Hong Gee Sim and Daniel W. Lin
35:   Late Events and Long Term Complications
Sophie Fossa and Jan Oldenburg
36:   Management of Non Germ Cell Testis
Jeffrey Holzbeierlein
37:   Signs, Symptoms, and Paraneoplastic Syndromes
Allan Pantuck

38:   Epidemiology of Renal Cell Carcinoma        
Wong-Ho Chow, Linda M. Dong, and Susan S. Devesa
39:   Pathology of Renal Cell Carcinoma
39A: Pathology of Sporadic Renal Neoplasms
Victor E. Reuter
39B: The Pathology of Hereditary Renal Cell Carcinoma Syndromes
Maria J. Merino
40:   Molecular and Clinical Prognostic Factors in Renal Cell Carcinoma
Brian Shuch, David S. Finley, Frederic Pouliot, and Arie S. Belldegrun
41:    Genetic Basis of Kidney Cancer
W. Marston Linehan, Ramaprasad Srinivasan and Laura Schmidt
42:   Radiologic Imaging of Renal Cell Carcinoma: Its Role in Diagnosis
 Peter L. Choyke
43:   Management of Small Renal Masses (SRMs)
43A: Natural History and Surveillance of Small Renal Masses   
Daniel Canter, Alexander Kutikov, Stephen A. Boorjian and Robert G. Uzzo
43B: The Role of Percutaneous Biopsies in Management of Small Renal Masses
Michael J. Leveridge and Michael A. S. Jewett
44:   Management of Localized Renal Cell Carcinoma
44A: Open Radical Nephrectomy for Localized Renal Cell Carcinoma
Steven C. Campbell
44B: Laparoscopic Radical Nephrectomy
Manish A. Vira and Louis R. Kavoussi
44C: Open Partial Nephrectomy  
Paul Russo
44D: Laparoscopic Partial Nephrectomy 
Manuel S. Eisenberga and Inderbir S. Gilla
44E: Robotic Partial Nephrectomy          
Ronald S. Boris, Gennady Bratslavsky, and Peter A. Pinto
44F: Ablation of Small Renal Masses       
Avi Beck, Aradhana M. Venkatesan, Bradford J. Wood, and Gennady Bratslavsky
44G: Management of Inherited Forms of Renal Cancer 
Gennady Bratslavsky, Peter A. Pinto, and W. Marston Linehan
44H: Surgical Management of Renal Cell Carcinoma: Role of Lymphadenectomy
Bradley C. Leibovich
45:   Management of Metastatic Renal Cell Carcinoma
45A: VEGF- Targeted Therapy in the Management of Metastatic Renal Cell Carcinoma
Jorge A. Garcia and Brian I. Rini
45B: mTOR Pathways and mTOR Inhibition in Renal Cell Carcinoma
Daniel C. Cho and Michael B. Atkins
45C: Immunotherapy in the Management of Renal Cell Carcinoma
Sumanta Kumar Pal, Karen Reckamp, Hua Yu and Robert A. Figlin
45D: Surgical Management of Metastatic/Advanced Kidney Cancer
Jose A. Karam and Christopher G. Wood
46:   Diagnosis, Epidemiology and Pathology of Penile Cancer
Alcides Chaux and Antonio L. Cubilla
47:   Surgical Management of Penile Cancer
Paul Russo and Simon Horenblas
48:   Radiation Therapy for Penile Cancer
Juanita M. Crook
49:   Chemotherapy for Penile Cancer
Lance C. Pagliaro
50:   Adrenal Neoplasms
MHD Yaser Al-Marrawi, Inderbir S. Gill, Ronald M. Bukowski, Brian I. Rini
51:   Diagnosis and Management of Pheochromocytoma
Jay S. Fonte, Jan Breza, W. Marston Linehan, Gennady Bratslavsky and Karel Pacak
52:   Genitourinary Sarcomas in Adults
Paul Russo
53:   Malignant Lymphoma of the Genitourinary Tract
Jeremy S. Abramson and M. Dror Michaelson
54:   Cancer of the Urethra
John J. Coen, Anthony H. Russell, and Guido Dalbagni
55:   Urachal Carcinoma – Contemporary Surgical Outcomes  
Harry W. Herr, Bernard H. Bochner, David Sharp, Guido Dalbagni, Victor E. Reuter
PROD-ECOMM2 nh2mk5fgx1skopgqqbap3ydh